within Pharmacolibrary.Drugs.ATC.J;

model J01MA13
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.88,
    Cl             = 0.00022666666666666666,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.124,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018500000000000003,
    Tlag           = 15.0,            
    Vdp             = 0.187,
    k12             = 11.8,
    k21             = 11.8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01MA13</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Trovafloxacin is a fluoroquinolone antibiotic that was previously used for the treatment of serious bacterial infections, including respiratory tract infections, intra-abdominal infections, and certain types of skin infections. Due to concerns over serious hepatotoxicity, it was withdrawn from the market in many countries and is no longer approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol><li><p>Vincent, J, et al., &amp; Friedman, HL (1998). Pharmacokinetics and metabolism of single oral doses of trovafloxacin. <i>American journal of surgery</i> 176(6A Suppl) 8S–13S. DOI:<a href=&quot;https://doi.org/10.1016/s0002-9610(98)00213-x&quot;>10.1016/s0002-9610(98)00213-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9935250/&quot;>https://pubmed.ncbi.nlm.nih.gov/9935250</a></p></li><li><p>Lacy, MK, et al., &amp; Quintiliani, R (1999). Oral bioavailability and pharmacokinetics of trovafloxacin in patients with AIDS. <i>Antimicrobial agents and chemotherapy</i> 43(12) 3005–3007. DOI:<a href=&quot;https://doi.org/10.1128/AAC.43.12.3005&quot;>10.1128/AAC.43.12.3005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10582898/&quot;>https://pubmed.ncbi.nlm.nih.gov/10582898</a></p></li><li><p>Garey, KW, &amp; Amsden, GW (1999). Trovafloxacin: an overview. <i>Pharmacotherapy</i> 19(1) 21–34. DOI:<a href=&quot;https://doi.org/10.1592/phco.19.1.21.30507&quot;>10.1592/phco.19.1.21.30507</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9917076/&quot;>https://pubmed.ncbi.nlm.nih.gov/9917076</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01MA13;
